肿瘤预防与治疗2024，Vol.37Issue(10)：918-924,7.DOI:10.3969/j.issn.1674-0904.2024.10.012
结直肠癌PD-1和PD-L1信号通路及免疫治疗研究现状与进展
Research Status and Progress of PD-1 and PD-L1 Signaling Pathways in and Immunotherapy for Colorectal Cancer
摘要
Abstract
Colorectal cancer has the high incidence and mortality in China.Great strides have been made in immunother-apy for solid tumors in recent years,giving hope to patients with colorectal cancer.However,the current DNA mismatch re-pair-deficient(dMMR)/microsatellite instability-high(MSI-H)colorectal cancer in response to immunotherapy accounts on-ly for about 10％,and DNA mismatch repair-proficient(pMMR)/microsatellite stable(MSS)colorectal cancer patients,which accounts for about 90％,cannot benefit from immunotherapy.As a result,immunotherapy for colorectal cancer cur-rently faces two states,'cold'and'hot'.Apart from dMMR/MSI-H,there is still a lack of effective biomarkers in colorec-tal cancer to identify suitable populations for immunotherapy.Therefore,in this review,we summarized the current research status of PD-1 and PD-L1 signaling pathways in and immunotherapy for colorectal cancer,and discussed issues such as im-munotherapy biomarkers,aiming to provide evidence for immunotherapy for colorectal cancer.关键词
结直肠癌/免疫治疗/PD-1/PD-L1/生物标志物Key words
Colorectal cancer/Immunotherapy/PD-1/PD-L1/Biomarker分类
医药卫生引用本文复制引用
计阳,李兆田,黄雪颖,燕锦..结直肠癌PD-1和PD-L1信号通路及免疫治疗研究现状与进展[J].肿瘤预防与治疗,2024,37(10):918-924,7.基金项目
四川省肿瘤医院优秀青年基金项目(编号:YB2024019) This study was supported by grants from Sichuan Cancer Hospital(No.YB2024019). （编号:YB2024019）
